Positive allosteric modulator of mGlu4 receptors (EC50 = 1.0 μM for human and rat mGlu4 receptors). Orally available and brain penetrant.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 197.24. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||5.07 mL||25.35 mL||50.7 mL|
|5 mM||1.01 mL||5.07 mL||10.14 mL|
|10 mM||0.51 mL||2.53 mL||5.07 mL|
|50 mM||0.1 mL||0.51 mL||1.01 mL|
References are publications that support the biological activity of the product.
East et al (2010) An orally bioavailable positive allosteric modulator of the mGlu4 receptor with efficacy in an animal model of motor dysfunction. Bioorg.Med.Chem.Lett. 20 4901 PMID: 20638279
If you know of a relevant reference for TCN 238, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: TCN 238, TCN 238 supplier, TCN238, metabotropic, glutamate, mglu4, positive, allosteric, modulators, pams, Glutamate, (Metabotropic), Group, III, Receptors, 4259, Tocris Bioscience
1 Citation for TCN 238
Citations are publications that use Tocris products. Selected citations for TCN 238 include:
Pershina and Arkhipov (2016) Subacute activation of mGlu4 receptors causes the feedback inhibition of its gene expression in rat brain. Life Sci. 153 50 PMID: 27055390
Do you know of a great paper that uses TCN 238 from Tocris? Please let us know.
Reviews for TCN 238
There are currently no reviews for this product. Be the first to review TCN 238 and earn rewards!
Have you used TCN 238?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.